Notícias e actividades

THE LANCET - Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients

THE LANCET - Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.
WHO - COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

WHO - COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

Worl Health OrganizationConcerns exists that angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs)increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19)...
NEJM - Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

NEJM - Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

The New England Journal of Medicine

Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.

CDC - Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19

CDC - Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19

Centers for Disease Control and PreventionIn the context of community transmission where continued testing is impractical, available evidence at this time indicates that an interim strategy based on time-since-illness-onset and...

ASSEMBLEIA DA REPÚBLICA

Medidas excecionais e temporárias de resposta à situação epidemiológica provocada pelo coronavírus SARS-CoV-2 e da doença COVID-19.

Centro Hospitalar e Universitário de Coimbra, E. P. E.

Criação do Biobanco de CHUC, EPE
Primeiro910111214161718Último
Categorias

Categorias

Arquivo de Notícias

Arquivo